Skip to main content
Have a personal or library account? Click to login
The Role of Monitoring the Bcr-Abl Transcript Levels in the Management of Patients with Chronic Myeloid Leukemia Cover

The Role of Monitoring the Bcr-Abl Transcript Levels in the Management of Patients with Chronic Myeloid Leukemia

Acta Marisiensis - Seria Medica
Volume 59 (2013): Issue 2 (April 2013)
By: ,  ,  ,  ,  ,   and    
Open Access
|Aug 2013
References

References

  1. 1. Copland M. Chronic myelogenous leukemia stem cells: What's new? Curr Hematol Malig Rep. 2009;4(2):66-73.
    Open DOISearch in Google Scholar
  2. 2. Deininger M, Goldman J, Melo J. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.
    Open DOISearch in Google Scholar
  3. 3. Serpa M, Sanabani SS, Dorliac-Llacer PE, Conchon M. Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission. BMC Blood Disorders. 2010;10:7.
    Search in Google Scholar
  4. 4. Pavlu J, Richard MSz, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. 2011;117:755-763.
    Search in Google Scholar
  5. 5. Belli C, Alú MF, Alfonso G, Bianchini M, Larripa I. Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism. Cytogenet Genome Res. 2011;132(4):304-8. Epub 2011 Jan 6.
    Open DOISearch in Google Scholar
  6. 6. Jabbour E, Cortes J, Kantarjian H. Optimal First-Line Treatment of Chronic Myeloid Leukemia: How to Use Imatinib and What Role for Newer Drugs? Oncology. 2007;21(6):653-62.
    Search in Google Scholar
  7. 7. Litzow MR. Imatinib resistance: obstacles and opportunities. Arch Pathol Lab Med. 2006;130:669-679.
    Open DOISearch in Google Scholar
  8. 8. Deininger MW. Milestones and Monitoring in Patients with CMLTreated with Imatinib. ASH Education Book. 2008;1:419-426.
    Search in Google Scholar
  9. 9. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.
    Open DOISearch in Google Scholar
  10. 10. Provan D, Singer RJ, Baglin T, Dokal I. Oxford Handbook of Clinical Hematology, Oxford University Press, third edition, Oxford, 2009, pg. 140-147.
    Open DOISearch in Google Scholar
  11. 11. Kantarjian HM, Shan J, Jones D, et al. Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome- Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response J Clin Oncol. 2009;27(22):3659-3663.
    Search in Google Scholar
DOI: https://doi.org/10.2478/amma-2013-0015 | Journal eISSN: 2668-7763 (formerly 2247-6113) | Journal ISSN: 2668-7755
Journal RSS Feed
Language: English
Page range: 71 - 74
Published on: Aug 13, 2013
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
monitoring CML,
RQ-PCR
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other

© 2013 Aliz-Beáta Tunyogi, I Benedek, Judit Beáta Köpeczi, Erzsébet Benedek, Enikő Kakucs, Monica Istrati, Zsuzsa Pap, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons License.

Volume 59 (2013): Issue 2 (April 2013)
Previous article
Next article